
Better science
better cancer detection
Easy to use, ex vivo and in vivo cancer detection that provides instantaneous, highly accurate results, without capital equipment.
NOVASCAN’S MISSION
Breakthrough Technology Improving Cancer Diagnosis
NovaScan’s leadership believes that improving the detection and stratification of cancer – be it in initial detection of cancer, during a procedure, or in post-procedural pathology – can improve patient outcomes, increase physician economics, and reduce the cost of care. We are committed to commercializing our platform technology for cancer detection and stratification, which we believe offers significant advantages over alternatives in soft tissue cancer detection. NovaScan’s first product, MarginScan Skin, offers dermatologists the opportunity for fast, predictable healthy tissue sparing skin cancer procedures.

NovaScan In the Press
PHC Corporation and NovaScan, Inc. Launch Collaboration to Explore the Feasibility of a Device that Supports Non-melanoma Skin Cancer Detection
PHC Corporation (headquarters: Minato-ku, Tokyo, President: Nobuaki Nakamura, hereafter PHC) and NovaScan, Inc. (headquarters: Chicago, Illinois, CEO: Craig Davis, hereafter NovaScan) announce the launch of a collaboration through which they will seek to explore the...
NovaScan’s nsCanary™ Tech Platform Named One of Five Finalists in AGA’s Shark Tank Competition
Program Recognizes Groundbreaking Technologies that Change the GI Landscape [MARCH 2, 2023 – CHICAGO, IL] NovaScan, a clinical stage oncology company, has been selected by the American Gastroenterological Association (AGA) as a finalist in its annual Shark Tank...
NovaScan Announces the Launch of a Human GI trial for its nsCanary™ Cancer Detection Device
Jan 9, 2023, Chicago, IL – NovaScan, a clinical stage oncology company based in Chicago, announced that it has started a human GI clinical trial for its nsCanary™ device at Texas International Endoscopy Center (TIEC), led by Principal Investigator Isaac Raijman MD....